Pfannenstiel P
Gesellschaft zur Förderung der Forschung, Deutsche Klinik für Diagnostike e. V., Wiesbaden.
Dtsch Med Wochenschr. 1988 Mar 4;113(9):326-31. doi: 10.1055/s-2008-1067639.
74 patients suffering from diffuse endemic goitre and with peripheric euthyrotic metabolism were treated for 6 months either with 150 micrograms levothyroxine (T4) daily (group I, n = 35), or with a combination of 100 micrograms levothyroxine and 130.8 micrograms potassium iodide (corresponding to 100 micrograms iodide) daily (group II, n = 39). This was followed in each case by a 3-month prophylactic administration of 100 micrograms iodide daily. After 3, 6 and 9 months the reduction of the goitre volumes--measured by sonography--was significantly different from the initial value in both groups. The reduction in goitre size was more marked in group II (-30.3%) than in group I (-25.2%), in each case after 6 months' treatment, but this difference was not significant. Suppression of the basal TSH levels in the serum coincided almost completely in both groups with an equidirectional increase after the subsequent iodide administration of 3 months' duration. Whereas in group I there was a renewed tendency towards thyroid enlargement under iodide prophylaxis, the diminution effect obtained in group II remained unchanged.
74例患有弥漫性地方性甲状腺肿且外周甲状腺功能正常的患者接受了为期6个月的治疗,其中一组(I组,n = 35)每日服用150微克左甲状腺素(T4),另一组(II组,n = 39)每日服用100微克左甲状腺素与130.8微克碘化钾(相当于100微克碘)的组合。随后,每组均进行为期3个月的每日100微克碘的预防性给药。在3个月、6个月和9个月时,通过超声测量的甲状腺肿体积减小情况与两组的初始值相比均有显著差异。在治疗6个月后,II组(-30.3%)的甲状腺肿缩小程度比I组(-25.2%)更明显,但这种差异并不显著。两组血清基础促甲状腺激素(TSH)水平的抑制情况在随后为期3个月的碘给药后几乎完全一致,且呈同向升高。在碘预防期间,I组出现了甲状腺再次肿大的趋势,而II组获得的缩小效果保持不变。